Delgocitinib is a topical treatment for chronic hand eczema, enhancing options for patients with severe symptoms.
Kevin Chamberlin, PharmD, FASCP
Advertisement
Kevin Chamberlin, PharmD, FASCP, is the associate vice president and chief pharmacy officer at UConn Health John Dempsey Hospital in Farmington, Connecticut.
Articles by Kevin Chamberlin, PharmD, FASCP
The approval expands options for protecting infants from respiratory syncytial virus, which remains a leading cause of pediatric hospitalization.
Advertisement
Latest Updated Articles
Delgocitinib Improves Patients’ Chronic Hand EczemaPublished: December 13th 2025 | Updated:
FDA Approves Enflonsia for the Prevention of RSV Lower Respiratory Tract Disease in InfantsPublished: October 21st 2025 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Congressional Spending Bill to Include Key PBM Contracting Reform
2
Pharma, OTC Supplement Are Markets Expected to Grow Billions Come 2032
3
Meeting at the Crossroads: The Role and Impact of PBMs and BOPs on Pharmacists
4
Q&A: New Medicare Drug Prices Proving Detrimental to Pharmacy Cashflow
5